|Day's range||1.2500 - 1.2500|
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.
Sanofi's (SNY) Dupixent succeeds in a pivotal study for COPD. FDA gives CRL to AbbVie's (ABBV) Parkinson's disease therapy, ABBV-951
Shares of drugmakers Sanofi and Regeneron surged more than 6% on Mar 23 on COPD drug data.